In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exelixis/GSK: Using Project Financing to Accelerate R&D

Executive Summary

Productivity in biotech is a better problem to have than its opposite-but paying the higher-than-expected development costs makes it still a problem. Thanks to a variety of new project financing sources, and a particularly clever approach to amending its alliance with GlaxoSmithKline, Exelixis is fact trying to turn research productivity into a source of non-dilutive capital.

Related Content

Symphony's Project Financing Model Adapts
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Private Equity Comes to Discovery
Big Pharma, Bigger Milestones
Will a New Accounting Change Cut Acquisition Values?
No Dilution Necessary: The Promise of Project Financing
Changing the Tires on a Moving Car: Restructured Alliances
Cytokinetics Stays the Course
Feeding the Machine: Exelixis Buys X-Ceptor
Symphony & Guilford Try Out Project Financing


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts